US · Healthcare · Biotechnology
EPS came in at -0.05 against a street estimate of -0.08 — a beat of 37.5%.
Analysts rate RenovoRx Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $7.12.
| Fund | Stake |
|---|---|
| AIGH Capital Management, LLC | 9.76% |
| Bleichroeder LP | 3.69% |
| Vanguard Capital Management, LLC | 3.21% |
| Geode Capital Management, LLC | 0.85% |
| Sontag Advisory LLC | 0.56% |
| Citadel Advisors Llc | 0.52% |
| Vanguard Fiduciary Trust Co | 0.35% |
| Northwestern Mutual Wealth Management Co | 0.22% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for RenovoRx Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.